glp 1 agonists and pancreatitis GLP-1 Pancreatitis Warnings Strengthened on GLP-1RAs

To further explore response variability, HTE and individualized treatment effect (ITE) analyses using advanced machine learning methods were incorporated to further identify subgroups of patients who may derive the maximal benefit or experience potential harm from GLP-1RA therapy in relation to cancer risk

PMID: 10905482

(2024, July 26)

Consistently, the E288 45.52b T mutation in GIPR reduced retatrutide-induced cAMP accumulation by 3.0-fold

Int J Clin Pract 70(8):649656 Yaribeygi H, Farrokhi FR, Abdalla MA, Sathyapalan T, Banach M, Jamialahmadi T, et al (2021) The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes